Long Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) (KETOHEART)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05781269 |
|
Recruitment Status :
Recruiting
First Posted : March 23, 2023
Last Update Posted : March 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The growing obesity pandemic has a major impact on global cardiovascular (CVD)-related morbidity and premature mortality, severely compromising the quality of life of those affected and significantly increasing costs for the healthcare system.
Numerous scientific evidences have demonstrated that a moderate weight loss (5-10% of the initial body weight) is already sufficient to determine the improvement of the cardiometabolic risk factors associated with overweight and obesity. With a view to obtaining a more significant weight loss in the initial stages of dietary treatment, in the last 10 years, the very low-calorie ketogenic diet (VLCKD) has become a strategy for the treatment of obesity and its comorbidities, also allowing to limit therapeutic failure and the high drop-out typical of traditional low-calorie diets.
The present study aims to study the long-term efficacy (36 months) of VLCKD in patients with severe obesity and metabolic syndrome, on weight loss, on single factors of the metabolic syndrome compared to a restrictive Mediterranean diet.
One hundred subjects with severe obesity and metabolic syndrome will be recruited and randomly assigned to VLCKD or to restrictive Mediterranean diet. Anthropometric parameters, metabolic status blood pressure, degree of arterial stiffness, prevalence and severity of snoring and OSA, cardiac systolic and diastolic function, the autonomic nervous control mode of the circulation will be evaluated at baseline, after one month and at the end of the study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity Morbid Obesity | Other: VLCKD Other: r-MedDiet | Not Applicable |
The present study aims to study the long-term efficacy (36 months) of VLCKD in patients with severe obesity and metabolic syndrome, on weight loss, on single factors of the metabolic syndrome, on the plasma concentration of specific adipokines and myokines on the properties of arterial wall, cardiovascular function, and sleep quantity and quality compared to a restrictive Mediterranean diet.
The studied population includes men and women between the ages of 55 and 75, with no documented history of CVD, severely obese (BMI ≥30 e <50 kg / m2) and at least three positive factors for metabolic syndrome. The patient, after consideration of inclusion and exclusion factors, are enrolled for 36 months and randomly divided into two groups (50 patients for group): group 1 is assigned to VLCKD diet treatment with medical food (VLCKD-group) whereas group 2 followed Mediterranean diet treatment (r-MedDiet). Medical Foods products are provided by Therascience. For both groups, the achievement of the objective is set as a variation of 20% compared to the initial weight. Throughout the study, the long-term efficacy of VLCKD compared with a restrictive Mediterranean diet will be evaluated on the modification of anthropometric parameters (weight, waist circumference, hip circumference, impedance test) metabolic status (using blood chemistry tests for the evaluation of Blood glucose, glycosylated hemoglobin, insulin, total cholesterol, HDL, triglycerides, adiponectin and irisin), blood pressure (by sphygmomanometer), degree of arterial stiffness (by Pulse Wave Velocity carotid-femoral), prevalence and severity of snoring and OSA (by polysomnography), cardiac systolic and diastolic function (by three-dimensional echocardiography), the autonomic nervous control mode of the circulation (by analysis HRV, Arterial Baroreflex Sensitivity). .
These evaluations will be carried out at pre-established and different times (T0-T22) during the entire duration of the study.
The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement. The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Metabolic Syndrome and Severe Obesity: Randomized Nutritional Trial to Study Long Term Effect of Very-low-calories Ketogenic Diet (VLCKD) on Weight Control and Cardiovascular Risk Factors |
| Actual Study Start Date : | February 20, 2022 |
| Estimated Primary Completion Date : | December 31, 2026 |
| Estimated Study Completion Date : | December 31, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: VLCKD-group
The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.
|
Other: VLCKD
VLCKD diet treatment with medical food |
|
Experimental: r-MedDiet
The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement
|
Other: r-MedDiet
Mediterranean diet treatment |
- change from baseline body weight at 36 months [ Time Frame: baseline, 36 month ]body weight measured to the nearest 0.1 Kg with a calibrated weight scale
- change from baseline fasting glucose in mg/dl at 36 months [ Time Frame: baseline, 36 month ]blood chemistry tests for the evaluation of blood glucose
- change from baseline HDL cholesterol, triglycerides at 36 months [ Time Frame: baseline, 36 month ]blood chemistry tests for the evaluation of HDL cholesterol, triglycerides
- change from baseline blood pressure in mmHg at 36 months [ Time Frame: baseline, 36 months ]measurement of systolic and diastolic pressure using using an aneroid sphygmomanometer with the appropriate cuff
- change from baseline distensibility of the carotid, radial and femoral arteries in m/s at 36 months [ Time Frame: baseline, 36 months ]arterial stiffness measured by Pulse Wave Velocity carotid-femoral
- change from baseline waist circumference in cm at 36 months [ Time Frame: baseline, 36 months ]waist circumference using a non-stretch tape to the nearest 0.5 cm
- change from baseline total and LDL cholesterol in mg/dl at 36 months [ Time Frame: baseline, 36 months ]blood chemistry tests for the evaluation of total cholesterol, LDL cholesterol
- change from baseline % of subjects with obstructive sleep apnea at 36 months [ Time Frame: baseline, 36 months ]apnea hypopnea index using polysomnography
- change from baseline cardiac systolic and diastolic function at 36 months [ Time Frame: baseline, 36 months ]evaluation of the cardiac systolic and diastolic function using by three-dimensional echocardiography
- change from baseline autonomic nervous control mode of the circulation at 36 months [ Time Frame: baseline, 36 months ]by analysis HRV, Arterial Baroreflex Sensitivity
- change from baseline insulin in mU/ml at 36 month [ Time Frame: baseline, 36 months ]blood chemistry tests for the evaluation of insulin
- change from baseline glycated hemoglobin in mmol/mol at 36 month [ Time Frame: baseline, 36 months ]blood chemistry tests for the evaluation of glycated hemoglobin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men between the ages of 55 and 75 with no documented history of CVD (except NYHA class I and II heart failure or valvular heart disease)
- Women aged 60 to 75, with no documented history of CVD (except NYHA class I and II heart failure or valvular heart disease)
- BMI ≥30 and <50kg/m2-At least three positive factors for metabolic syndrome according to the harmonized definition (IDF --------2009)
- Availability to be followed in the follow-up at the San Michele Hospital IRCCS Istituto Auxologico Italiano in Milan
Exclusion Criteria:
- Long QT >0.44 s, known arrhythmia, cardiomyopathy, heart failure (NYHA classes III-IV)
- Hypokalemia, hypernatremia
- Persistent diarrhea
- Acidosis (metabolic or respiratory) even if compensated
- Acute heart failure, transient ischemic attack or stroke in the previous 12 months
- Pregnancy or breastfeeding
- chronic renal insufficiency (creatinine >1.5 and/or creatinine clearance <45 mL/min), history -positive for previous episodes of acute renal failure
- Autoimmune diseases (TCA relative contraindication)
- History of previous pancreatitis
- Symptomatic cholelithiasis
- Hepatic insufficiency and/or ALT and AST > 3 times the upper limit
- Stubborn constipation or history of intestinal occlusions/subocclusions
- Type 1 diabetes
- History of previous cancer within the first 5 years of follow-up
- Active eating disorder or history of bulimia and anorexia nervosa, active severe binge eating,
- Psychiatric disorders not in compensation or at risk of decompensation
- Alcoholism, substance abuse
- Ongoing pharmacological therapy with topiramate, zonisamide, acetazolamide, valproic acid- - ----- - chronic therapy with diuretics (which cannot be suspended even temporarily), SGLT2 -inhibitors (due to the risk of euglycemic diabetic ketoacidosis) and beta blockers.
- Known primary pathologies of carnitine metabolism or beta oxidation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05781269
| Contact: Luisa Gilardini, MD | +3902619112561 | l.gilardini@auxologico.it |
| Italy | |
| Istituto Auxologico Italiano | Recruiting |
| Milano, Italy, 20145 | |
| Contact: LUISA GILARDINI, MD +3902619112561 l.gilardini@auxologico.it | |
| Study Chair: | Simona Bertoli, MD | Istituto Auxologico Italiano |
| Responsible Party: | Istituto Auxologico Italiano |
| ClinicalTrials.gov Identifier: | NCT05781269 |
| Other Study ID Numbers: |
43J001 |
| First Posted: | March 23, 2023 Key Record Dates |
| Last Update Posted: | March 23, 2023 |
| Last Verified: | March 2023 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
VLCKD obesity metabolic syndrome cardiovascular risk |
|
Obesity Obesity, Morbid Overweight |
Overnutrition Nutrition Disorders Body Weight |